Tasly Pharmaceutical Group: Some products price reduction led to a decline in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Focus on earnings conference

① Affected by the overall low prosperity of the pharmacy industry, the company's pharmaceutical commerce sector saw a decline in revenue in the third quarter this year; the pharmaceutical industry sector's revenue grew year-on-year, but price reductions on some products led to a decrease in gross margin, and the company expects the gross margin to remain stable in the future. ② Regarding the equity trade matters between the company's major shareholder and china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting various works for this transaction.

cls.cnNov 27 22:29

Clinical results did not meet expectations, tasly pharmaceutical group suspends the eight-year development "marathon" of the new cancer drug | Quick read announcement.

① Tasly Pharmaceutical Group announced the suspension of research and development for its Anmeimuk monoclonal antibody, which has reached the phase IIb clinical research stage since its approval in 2016; ② According to clinical research results, the efficacy of Anmeimuk did not meet expectations, and competition with other EGFR monoclonal antibody biosimilars is intense; ③ This project also involves Sirun Pharmaceutical's shareholding, with Tasly Pharmaceutical Group and Sirun Pharmaceutical recording asset impairment losses of 0.162 billion yuan and 14.1448 million yuan, respectively.

cls.cnNov 23 00:06

China Resources Sanjiu Medical & Pharmaceutical's 6.2 billion yuan acquisition of Tasly Pharmaceutical Group is gradually taking shape in the traditional Chinese medicine sector. | Speed read announcement

China Resources Sanjiu Medical & Pharmaceutical spent 6.2 billion yuan to acquire 28% of Tasly Pharmaceutical Group's shares, becoming the controlling shareholder of Tasly. This transaction is helpful for China Resources Sanjiu Medical & Pharmaceutical to accelerate the supplement of innovative traditional Chinese medicine pipelines, improve research and development capabilities of innovative drugs, establish a leading advantage in the traditional Chinese medicine field, and enable both sides to have a synergistic effect in the traditional Chinese medicine industry chain, in areas such as traditional Chinese medicinal materials cultivation, innovative research and development, intelligent manufacturing, and channel marketing.

cls.cnAug 4 22:50

After two years of state-owned enterprise acquisition, Henan Taloph Pharmaceutical Stock is becoming increasingly outward-looking in the traditional Chinese medicine industry. | Industry research series

① The company plans to use the brand awareness and high market share marketing system of its core product Shuanghuanglian Oral Liquid to enhance the overall sales growth of the entire oral liquid business; ② As the subsidiary Tongjuntang won the honorary title of China's time-honored brand, it provided an opportunity for Tailong Pharmaceutical to enter the field of traditional Chinese medicine health; ③ After the company was included as the main enterprise in the biomedical industry chain in Zhengzhou, the intensity of foreign investment also increased markedly.

cls.cnJun 30 22:00

Received investment from pharmaceutical companies such as Tiger and Tessile, Peger Biotech relaunches its IPO and bets on GLP-1 in the future

① Peger Biotech has one GLP-1 product, PB-119, which is in the NDA stage, and five other products under clinical and pre-clinical development; ② Since the core product has not yet been approved, Peger Biotech is still in a “three no” state with “no products, no revenue, no profit”.

cls.cnMar 5 11:31

Is performance returning to growth and stock prices still underestimated? Harbin Pharmaceutical Co., Ltd. was called out by investors for “market value management” | Direct impact on performance meetings

① Harbin Pharmaceutical Co., Ltd. handed over excellent performance results in the third quarter, but investors called for an increase in stock prices eight times at the performance meeting. ② Company director Lin Guoren said that the company attaches importance to market value management while strengthening investor relations management activities. ③ Investors are also concerned about issues such as collection, mycoplasma pneumonia drugs, and product layout in the field of old-age care.

cls.cnNov 9, 2023 19:42